Abstract
Conflicting data and substantial controversy exist regarding optimal adjuvant treatment for those patients with resectable or potentially resectable adenocarcinoma of the pancreas. Despite improvements in short-term surgical outcomes, the use of newer chemotherapeutic agents, development of targeted agents and more precise delivery of radiation, the 5-year survival rates for early-stage patients remains less than 25%. This article critically reviews the existing data for various adjuvant treatment approaches for patients with surgically resectable pancreatic cancer. Our review confirms that despite several randomized clinical trials, the optimal adjuvant treatment approach for these patients remains unclear.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 469-480 |
| Number of pages | 12 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 12 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2012 |
Fingerprint
Keywords
- biological markers
- combined modality therapy
- molecular targets
- neoadjuvant
- pancreatic adenocarcinoma
- radiotherapy
ASJC Scopus subject areas
- Pharmacology (medical)
- Oncology
Cite this
The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. / Kimple, Randall J.; Russo, Suzanne; Monjazeb, Arta M; Blackstock, A. William.
In: Expert Review of Anticancer Therapy, Vol. 12, No. 4, 04.2012, p. 469-480.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer
AU - Kimple, Randall J.
AU - Russo, Suzanne
AU - Monjazeb, Arta M
AU - Blackstock, A. William
PY - 2012/4
Y1 - 2012/4
N2 - Conflicting data and substantial controversy exist regarding optimal adjuvant treatment for those patients with resectable or potentially resectable adenocarcinoma of the pancreas. Despite improvements in short-term surgical outcomes, the use of newer chemotherapeutic agents, development of targeted agents and more precise delivery of radiation, the 5-year survival rates for early-stage patients remains less than 25%. This article critically reviews the existing data for various adjuvant treatment approaches for patients with surgically resectable pancreatic cancer. Our review confirms that despite several randomized clinical trials, the optimal adjuvant treatment approach for these patients remains unclear.
AB - Conflicting data and substantial controversy exist regarding optimal adjuvant treatment for those patients with resectable or potentially resectable adenocarcinoma of the pancreas. Despite improvements in short-term surgical outcomes, the use of newer chemotherapeutic agents, development of targeted agents and more precise delivery of radiation, the 5-year survival rates for early-stage patients remains less than 25%. This article critically reviews the existing data for various adjuvant treatment approaches for patients with surgically resectable pancreatic cancer. Our review confirms that despite several randomized clinical trials, the optimal adjuvant treatment approach for these patients remains unclear.
KW - biological markers
KW - combined modality therapy
KW - molecular targets
KW - neoadjuvant
KW - pancreatic adenocarcinoma
KW - radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=84859795721&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859795721&partnerID=8YFLogxK
U2 - 10.1586/era.12.18
DO - 10.1586/era.12.18
M3 - Article
C2 - 22500684
AN - SCOPUS:84859795721
VL - 12
SP - 469
EP - 480
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
SN - 1473-7140
IS - 4
ER -